Pro-Symbioflor

Informazioni principali

  • Nome commerciale:
  • Pro-Symbioflor Sospensione
  • Forma farmaceutica:
  • Sospensione
  • Composizione:
  • enterococcus faecalis vivus 15-45 Mio U., escherichia coli viva 15-45 Mio U., excipiens annuncio suspensionem pro 1 ml.
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Pro-Symbioflor Sospensione
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Bakterien - und Hefepräparate
  • Area terapeutica:
  • funktionelle Störungen des Magen-Darmtraktes insbesondere Reizdarm (Colon irritabile)

Altre informazioni

Status

  • Fonte:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Numero dell'autorizzazione:
  • 675
  • Data dell'autorizzazione:
  • 04-10-2005
  • Ultimo aggiornamento:
  • 17-10-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Patienteninformation

Transferiert von Ebi-Pharm AG

Pro-Symbioflor

Biomed AG

Che cos'è Pro-Symbioflor e quando si usa?

Pro-Symbioflor è un immunostimolante (preparato destinato ad incrementare le difese proprie

dell'organismo) e contiene i componenti cellulari di batteri di origine naturale appartenenti ai generi

Enterococcus faecalis ed Escherichia coli, che influenzano favorevolmente il sistema immunitario

nel tratto intestinale. Pro-Symbioflor serve per la cura di disturbi funzionali del tratto

gastrointestinale, specialmente nei casi di colon irritabile.

Quando non si può assumere Pro-Symbioflor?

In caso di ipersensibilità ad uno dei suoi componenti. Pro-Symbioflor non deve essere assunto in

presenza di gravi malattie organiche dell'apparato gastrointestinale, quali infiammazioni della

cistifellea e del pancreas, e in caso di occlusione intestinale. Durante indisposizioni febbrili acute si

dovrebbe interrompere temporaneamente l'assunzione di Pro-Symbioflor.

Quando è richiesta prudenza nella somministrazione di Pro-Symbioflor?

1 ml contiene 4,9 mg di lattosio. Per persone con intolleranze note al lattosio è richiesta prudenza

nell'uso di Pro-Symbioflor. Non sono noti effetti sulla capacità di reazione, sulla capacità di condurre

veicoli e sulla capacità di utilizzare attrezzi o macchine.

Informi il suo medico o il suo farmacista se

·soffre di altre malattie,

·soffre di allergie o

·assume altri medicamenti (anche se acquistati di sua iniziativa!).

Si può assumere Pro-Symbioflor durante la gravidanza o l'allattamento?

Se la paziente ha in corso o in programma una gravidanza o se allatta, dovrebbe prendere Pro-

Symbioflor soltanto su espressa prescrizione del suo medico o del suo farmacista, informato della

situazione.

Come usare Pro-Symbioflor?

Istruzioni sulla posologia: Gli adulti all'inizio del trattamento devono assumere 5 gocce 3 volte al

giorno. Entro due settimane la dose dovrà essere aumentata a 20 gocce 3 volte al giorno. Bambini:

ridurre la dose (p.es. 5 gocce 3 volte al giorno, da aumentare a 10 gocce 3 volte al giorno entro 2

settimane). Scuotere bene il flaconcino di Pro-Symbioflor prima dell'uso! Il prodotto si intorbidirà

leggermente. Prendere le gocce ai pasti con un po' d'acqua. Qualora all'inizio del trattamento

comparissero sintomi di flatulenze e di disturbi addominali, bisognerebbe prendere le gocce di Pro-

Symbioflor più diluite o in quantità minori, oppure aumentare più lentamente il numero delle gocce.

Durata del trattamento: La durata della cura dipende dalla gravità dell'indisposizione ed è

generalmente di 4-6 settimane. Si attenga alla posologia indicata nel foglietto illustrativo o prescritta

dal medico. Se ritiene che l'azione del medicamento sia troppo debole o troppo forte, ne parli al suo

medico o al suo farmacista.

Quali effetti collaterali può avere Pro-Symbioflor?

Con l'assunzione o l'applicazione di Pro–Symbioflor possono manifestarsi i seguenti effetti

collaterali: All'inizio del trattamento possono manifestarsi occasionalmente gonfiori al ventre,

emissione d'aria o disturbi addominali.

Se osserva effetti collaterali qui non descritti dovrebbe informarne il suo medico o il suo farmacista.

Di che altro occorre tener conto?

Il medicamento non dev'essere utilizzato oltre la data indicata con «Exp.» sulla confezione. Pro-

Symbioflor deve essere conservato nella confezione originale chiusa a temperatura non inferiore a

2 °C e non superiore a 25 °C, e fuori della portata dei bambini. Chiudere bene il flacone subito dopo

l'uso. Il flacone, una volta aperto, va conservato per non oltre 2 settimane nel frigorifero (2 °C – 8

°C). Annotare sul flacone la data della prima apertura. Pro-Symbioflor non contiene conservanti e

quindi, in caso d'uso non corretto, è esposto a contaminazioni. Queste si potranno evitare aprendo il

flacone per l'uso molto brevemente e facendone gocciolare il contenuto con cautela. Non toccare il

contagocce con le dita! Qualora dopo la prima apertura del flacone si manifestino alterazioni

dell'odore o del sapore, quel flacone di Pro-Symbioflor non dovrà più essere usato.

Il medico o il farmacista, che sono in possesso di documentazione professionale, possono darle

ulteriori informazioni.

Cosa contiene Pro-Symbioflor?

1 ml (= 14 gocce) di Pro-Symbioflor contiene come principio attivo componenti cellulari dei batteri

Enterococcus faecalis ed Escherichia coli ( 1,5–4,5× 107 di batteri), lattosio ed altre sostanze

ausiliarie.

Numero dell'omologazione

00675 (Swissmedic).

Dove è ottenibile Pro-Symbioflor? Quali confezioni sono disponibili?

In farmacia senza prescrizione medica.

Confezione con un flacone contagocce da 50 ml.

Titolare dell'omologazione

Biomed AG, Überlandstrasse 199, CH-8600 Dübendorf.

Questo foglietto illustrativo è stato controllato l'ultima volta nel maggio 2005 dall'autorità

competente in materia di medicamenti (Swissmedic).

19-12-2018

Wegmans Issues Voluntary Recall of Fresh Cauliflower Rice, Veggie/Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower

Wegmans Issues Voluntary Recall of Fresh Cauliflower Rice, Veggie/Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower

Rochester, NY – Wegmans Food Markets, Inc. has issued a voluntary recall of fresh Cauliflower Rice, Veggie Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower, sold in the produce department between 12/7/18 and 12/18/18, because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with bloody stools. Although most healthy adults can recover completely within a week, some people can develop a form of kidney failure called He...

FDA - U.S. Food and Drug Administration

18-12-2018

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. of Santa Maria, California is recalling red leaf lettuce, green leaf lettuce and cauliflower harvested on November 27 through 30, 2018 out of an abundance of caution, because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7).

FDA - U.S. Food and Drug Administration

16-12-2018

Spokane Produce Voluntarily Recalls Northwest Cuisine Creations and Fresh&Local Sandwiches and Green Leaf Lettuce Filets

Spokane Produce Voluntarily Recalls Northwest Cuisine Creations and Fresh&Local Sandwiches and Green Leaf Lettuce Filets

Spokane Produce Inc. of Spokane, WA initiates a voluntary recall of sandwiches containing green leaf lettuce and foodservice lettuce filets following notice of a produce industry ingredient recall by Adam Bros. Farming Inc. Sandwich products bearing the Northwest Cuisine Creations and Fresh&Local labels. These prod- ucts are recalled because they may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with bloody stools. Although most...

FDA - U.S. Food and Drug Administration

13-12-2018

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

Published on: Wed, 12 Dec 2018 This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring activities carried out in 2017 in 37 European countries (28 Member States (MS) and nine non-MS). Campylobacteriosis was the commonest reported zoonosis and its EU trend for confirmed human cases increasing since 2008 stabilised during 2013–2017. The decreasing EU trend for confirmed human salmonellosis cases since 2008 end...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Published on: Fri, 16 Nov 2018 The applicant BASF Agro B.V. submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for picolinafen in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new validated analytical method for enforcement of the residue in dry/high starch‐, high water content‐, high acid content‐ and high oil content commodities ...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea

FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

FDA - U.S. Food and Drug Administration

26-10-2018

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Published on: Thu, 25 Oct 2018 00:00:00 +0200 The product subject of this assessment is l‐threonine produced by fermentation with a genetically modified strain of Escherichia coli (CGMCC 7.232). It is intended to be used in feed and water for drinking for all animal species and categories. The production strain and its recombinant DNA were not detected in the additive. The product l‐threonine, manufactured by fermentation with E. coli CGMCC 7.232, does not raise any safety concern with regard to the gen...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation is voluntarily recalling all of its products produced at the Keaau facility between Sept. 6 - 21, 2018 due to a potential contamination of Escherichia coli (E. coli). The recall was initiated due to E. coli being detected in the well water and distribution system that supplies the firm's operations. No illnesses related to the water have been reported to the state.

FDA - U.S. Food and Drug Administration

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Modelling of inactivation through heating for quantitative microbiological risk assessment (QMRA)

Modelling of inactivation through heating for quantitative microbiological risk assessment (QMRA)

Published on: Mon, 27 Aug 2018 00:00:00 +0200 EFSA regards the household as a stage in the food chain that is important for the final number of food‐borne infections. The fate of a pathogen in the private kitchen largely depends on consumer hygiene during preparation of food and on its proper cooking, especially in the case of meat. Unfortunately, detailed information on the microbiological survival in meat products after heating in the consumer kitchen is lacking. The aim of the study was to improve th...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

21-5-2018

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Manufacturing products without proper process controls increases the probability that products will vary in strength, quality and purity

FDA - U.S. Food and Drug Administration

18-5-2018

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. is voluntarily recalling all lots of homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir, within expiry, to the consumer level. The drug products have been found to be manufactured with a lack of adequate controls.

FDA - U.S. Food and Drug Administration

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Europe - EMA - European Medicines Agency